Please ensure Javascript is enabled for purposes of website accessibility

Why Tyme Technologies Is Skyrocketing

By Brian Feroldi – Updated Apr 18, 2019 at 10:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares rose sharply after management released upbeat clinical data and scheduled a conference call.

What happened

Investors in Tyme Technologies (TYME), a clinical-stage biotechnology focused on cancer, are having a great day. Shares are up 54% as of 3:46 p.m. EST, after management released preliminary data from a phase 2 trial and scheduled a conference call to discuss the results.

So what

Tyme is holding a call with investors on Friday at 9 a.m. EST to discuss data from a phase 2 trial, which is testing its compound SM-88 as a hopeful treatment for pancreatic cancer.

The abstract from the study was published earlier today on the American Society of Clinical Oncology's (ASCO's) website.

Scientists working in a lab

Image source: Getty Images.

The data that seems to have traders feeling giddy today was that 3 out of 4 evaluable subjects appeared to be responding to the treatment. In addition, the drug was shown to be well-tolerated by patients, as no treatment-related grade 4 or 5 events occurred.

This data suggest that SM-88 might be the real deal.

Now what

This initial data release is certainly encouraging, but it's hard to draw any real conclusions about SM-88 since we're only talking about four patients. The reason the reported number of patients is so small is that the abstract only includes patient data that met ASCO's abstract submission deadline of Sept. 25. At that time, the majority of patients had been on trial for less than one month.

Management plans on providing investors with up-to-date clinical data through January when it holds its call on Friday. Bulls and bears alike will want to tune in to get the latest read on SM-88.

Check out all our earnings call transcripts.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Tyme Technologies, Inc. Stock Quote
Tyme Technologies, Inc.
TYME

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.